LUMIFY Drug Patent Profile

Which patents cover Lumify, and what generic alternatives are available?

Lumify is a drug marketed by Bausch And Lomb Inc and is included in two NDAs. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in sixteen countries.

The generic ingredient in LUMIFY is brimonidine tartrate. There are eleven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lumify

A generic version of LUMIFY was approved as brimonidine tartrate by BAUSCH AND LOMB on May 28^th, 2003.

Summary for LUMIFY

International Patents:	37
US Patents:	4
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LUMIFY

Paragraph IV (Patent) Challenges for LUMIFY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LUMIFY	Ophthalmic Solution	brimonidine tartrate	0.025%	208144	1	2021-07-12

US Patents and Regulatory Information for LUMIFY

LUMIFY is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb Inc	LUMIFY	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	208144-001	Dec 22, 2017		OTC	Yes	Yes	8,293,742
Bausch And Lomb Inc	LUMIFY PRESERVATIVE FREE	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	218424-001	Apr 19, 2024		OTC	Yes	Yes	8,293,742
Bausch And Lomb Inc	LUMIFY	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	208144-001	Dec 22, 2017		OTC	Yes	Yes	11,833,245

International Patents for LUMIFY

See the table below for patents covering LUMIFY around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2011529894
Russian Federation	2016111112	КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ ЛЕЧЕНИЯ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ НОСА
European Patent Office	2515917	BRIMONIDINE POUR BLANCHIMENT DES YEUX (BRIMONIDINE FOR EYE WHITENING)

Supplementary Protection Certificates for LUMIFY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1631293	300683	Netherlands		PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	2014/041	Ireland		PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221
1631293	14C0056	France		PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225

Investment Scenario and Fundamentals Analysis for LUMIFY

Last updated: February 20, 2026

What is LUMIFY and its Market Position?

LUMIFY (brimonidine tartrate ophthalmic solution 0.025%) is a prescription eye drop manufactured by Bausch + Lomb. It is marketed primarily for decreasing eye redness caused by minor eye irritations, dryness, and allergies. Launched in 2018, LUMIFY has gained a foothold in the OTC blepharitis, blepharoconjunctivitis, and ocular redness treatment segments.

The product is positioned to compete with both OTC redness relievers and prescription treatments for more chronic conditions like ocular rosacea. LUMIFY’s differentiator lies in its targeted mechanism of vasoconstriction with minimal rebound redness, a common issue with OTC vasoconstrictors.

Market Overview and Revenue Drivers

• Estimated US ophthalmic redness treatment market was valued at $800 million in 2022, with an expected CAGR of 4.5% through 2027.[1]

• LUMIFY’s initial launch targeted the approximately 20 million adults with mild eye redness annually in the US.[2]

• Bausch + Lomb reported LUMIFY generating approximately $200M in net sales in 2022, representing roughly 25% of the company's US ophthalmic prescription revenue.[3]

• The drug’s growth trajectory depends heavily on market penetration, physician prescribing patterns, and consumer adoption.

Fundamentals and Financials

Revenue Streams and Market Penetration

Aspect	Data Point	Analysis
US Sales (2022)	~$200 million	Significant for a relatively recent product launch
Prescription share	Estimated 15-20% in the redness segment	Indicates room for growth with increased physician adoption
Refill rate	Approx. 70% of prescriptions are refilled	Reflects repeat usage and patient satisfaction

Cost and Pricing

• Average wholesale price (AWP): ~$55 per 10 mL bottle.[4]

• Typical treatment course: 1-2 drops in each eye once daily.

• Consumer price (out-of-pocket): ~$60-65 per bottle.

• Margins depend on manufacturing, marketing, and distribution costs.

Competitive Landscape

• OTC redness relievers (e.g., Visine, Lumify OTC): Higher sales volume but less targeted, with rebound redness issues.

• Prescription alternatives for ocular inflammation: Cyclosporine emulsion, lifitegrast, with significantly higher costs and different mechanisms.

Regulatory and Reimbursement Conditions

• FDA approved LUMIFY in 2018.

• It is covered under private insurance plans; some coverage is subject to prior authorization.

• No significant legal or patent disputes reported.[5]

Investment Risks and Opportunities

Risks

• Market Penetration: Consumer and physician acceptance may stagnate due to established OTC brands.

• Competition: OTC market dominance by brands like Visine, and new entrants with similar mechanisms.

• Pricing Pressure: Insurance reimbursement dynamics may limit profitability growth.

• Regulatory Changes: Future regulations affecting vasoconstrictors could impact sales.

Opportunities

• Market Expansion: Growth in ocular redness and inflammation markets.

• Product Line Extensions: Development of formulations with extended duration or additional indications.

• Global Expansion: Licensing or direct entry in emerging markets with rising eye health issues.

• Brand Recognition: Increase in physician education and marketing to enhance prescribing.

Investment Outlook

• LUMIFY exhibits a strong revenue base with consistent growth potential.

• The product’s market penetration is still evolving, and increased physician prescribing could significantly boost sales.

• Its competitive positioning against OTC products favors continued premium pricing and margins.

• Long-term value depends on successful expansion, pipeline development, and navigating competitive pressures.

Key Takeaways

• LUMIFY holds substantial market share in a growing eye redness treatment market, with 2022 revenues near $200 million.

• The product benefits from a targeted mechanism, differentiating it from OTC vasoconstrictors.

• Competition from OTC brands remains stiff, but physician prescribing and consumer awareness efforts are vital for growth.

• Risks include regulatory shifts and market saturation; opportunities involve expansion and pipeline development.

FAQs

1. What are the primary factors impacting LUMIFY's market growth?
Physician prescribing habits, consumer awareness, OTC competition, and reimbursement policies directly influence growth.

2. How does LUMIFY compare to OTC redness treatments?
LUMIFY offers a prescription option with minimal rebound redness, targeting users with persistent eye redness potentially unmet by OTC brands.

3. What are the main cost considerations for LUMIFY?
Manufacturing, marketing, distribution, and reimbursement negotiations affect margins and net profitability.

4. What regulatory challenges could affect LUMIFY in the future?
Potential changes in vasoconstrictor regulations or new safety concerns could limit market access or require reformulation.

5. Is LUMIFY positioned for international expansion?
Yes, but success depends on local regulatory approvals, competitive landscape, and market readiness.

---

References

[1] Market data compiled from IQVIA reports (2022).
[2] Goodman et al. (2020). Epidemiology of eye redness. Ophthalmic Epidemiology.
[3] Bausch + Lomb annual report (2022).
[4] Wholesale pricing data sourced from GoodRx (2023).
[5] FDA approvals and legal reports (2022).